 | • レポートコード：MRC23Q35890 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の複合化学療法市場について調査・分析し、世界の複合化学療法市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（重量式自動調合装置、容量式自動調合装置）、用途別セグメント分析（乳がん、血液がん、前立腺がん、消化器がん、呼吸器/肺がん、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Braun Melsungen AG、Pfizer Inc.、Baxter、Grifols SA、The Metrix Company、Added Pharma、Equashield、Millers Pharmacy、Comecer S.P.A.、Omnicell、Icon group、Dedalus Group、Arxium、Sterline S.R.L.、Loccioniなどが含まれています。世界の複合化学療法市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、複合化学療法市場規模を推定する際に考慮しました。本レポートは、複合化学療法の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、複合化学療法に関するビジネス上の意思決定に役立てることを目的としています。 ・複合化学療法市場の概要 - 複合化学療法のタイプ別セグメント - 世界の複合化学療法市場規模：タイプ別分析（重量式自動調合装置、容量式自動調合装置） - 複合化学療法の用途別セグメント - 世界の複合化学療法市場規模：用途別分析（乳がん、血液がん、前立腺がん、消化器がん、呼吸器/肺がん、その他） - 世界の複合化学療法市場規模予測（2018年-2029年） ・複合化学療法市場の成長トレンド - 複合化学療法の地域別市場規模（2018年-2029年） - 複合化学療法市場ダイナミクス - 複合化学療法の業界動向 - 複合化学療法市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：重量式自動調合装置、容量式自動調合装置 - 世界の複合化学療法のタイプ別市場規模（2018年-2023年） - 世界の複合化学療法のタイプ別市場規模（2024年-2029年） ・用途別セグメント：乳がん、血液がん、前立腺がん、消化器がん、呼吸器/肺がん、その他 - 世界の複合化学療法の用途別市場規模（2018年-2023年） - 世界の複合化学療法の用途別市場規模（2024年-2029年） ・複合化学療法の地域別市場規模 - 北米の複合化学療法市場規模（2018年-2029年） - アメリカの複合化学療法市場規模（2018年-2029年） - ヨーロッパの複合化学療法市場規模（2018年-2029年） - アジア太平洋の複合化学療法市場規模（2018年-2029年） - 中国の複合化学療法市場規模（2018年-2029年） - 日本の複合化学療法市場規模（2018年-2029年） - 韓国の複合化学療法市場規模（2018年-2029年） - インドの複合化学療法市場規模（2018年-2029年） - オーストラリアの複合化学療法市場規模（2018年-2029年） - 中南米の複合化学療法市場規模（2018年-2029年） - 中東・アフリカの複合化学療法市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Braun Melsungen AG、Pfizer Inc.、Baxter、Grifols SA、The Metrix Company、Added Pharma、Equashield、Millers Pharmacy、Comecer S.P.A.、Omnicell、Icon group、Dedalus Group、Arxium、Sterline S.R.L.、Loccioni ・アナリストの観点/結論 ・調査方法とデータソース |
The compounding chemotherapy market is showing significant growth. Compounding of drugs makes them patient-specific which is the biggest advantage. Compounding chemotherapy can minimize the risk of underdose or overdose of drugs for a patient. Therefore, owing to its numerous advantages.
Highlights
The global Compounding Chemotherapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Compounding Chemotherapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Compounding Chemotherapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Compounding Chemotherapy in Breast Cancer is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Compounding Chemotherapy include Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy and Comecer S.P.A., etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Compounding Chemotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Compounding Chemotherapy.
The Compounding Chemotherapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Compounding Chemotherapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Compounding Chemotherapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Braun Melsungen AG
Pfizer Inc.
Baxter
Grifols SA
The Metrix Company
Added Pharma
Equashield
Millers Pharmacy
Comecer S.P.A.
Omnicell
Icon group
Dedalus Group
Arxium
Sterline S.R.L.
Loccioni
Segment by Type
Gravimetric Automated Compounding Device (Weight-Based)
Volumetric Automated Compounding Device (Volume-Based)
Segment by Application
Breast Cancer
Blood Cancer
Prostate Cancer
Gastrointestinal Cancer
Respiratory/Lung Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Compounding Chemotherapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Compounding Chemotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Gravimetric Automated Compounding Device (Weight-Based)
1.2.3 Volumetric Automated Compounding Device (Volume-Based)
1.3 Market by Application
1.3.1 Global Compounding Chemotherapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Breast Cancer
1.3.3 Blood Cancer
1.3.4 Prostate Cancer
1.3.5 Gastrointestinal Cancer
1.3.6 Respiratory/Lung Cancer
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Compounding Chemotherapy Market Perspective (2018-2029)
2.2 Compounding Chemotherapy Growth Trends by Region
2.2.1 Global Compounding Chemotherapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Compounding Chemotherapy Historic Market Size by Region (2018-2023)
2.2.3 Compounding Chemotherapy Forecasted Market Size by Region (2024-2029)
2.3 Compounding Chemotherapy Market Dynamics
2.3.1 Compounding Chemotherapy Industry Trends
2.3.2 Compounding Chemotherapy Market Drivers
2.3.3 Compounding Chemotherapy Market Challenges
2.3.4 Compounding Chemotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Compounding Chemotherapy Players by Revenue
3.1.1 Global Top Compounding Chemotherapy Players by Revenue (2018-2023)
3.1.2 Global Compounding Chemotherapy Revenue Market Share by Players (2018-2023)
3.2 Global Compounding Chemotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Compounding Chemotherapy Revenue
3.4 Global Compounding Chemotherapy Market Concentration Ratio
3.4.1 Global Compounding Chemotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Compounding Chemotherapy Revenue in 2022
3.5 Compounding Chemotherapy Key Players Head office and Area Served
3.6 Key Players Compounding Chemotherapy Product Solution and Service
3.7 Date of Enter into Compounding Chemotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Compounding Chemotherapy Breakdown Data by Type
4.1 Global Compounding Chemotherapy Historic Market Size by Type (2018-2023)
4.2 Global Compounding Chemotherapy Forecasted Market Size by Type (2024-2029)
5 Compounding Chemotherapy Breakdown Data by Application
5.1 Global Compounding Chemotherapy Historic Market Size by Application (2018-2023)
5.2 Global Compounding Chemotherapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Compounding Chemotherapy Market Size (2018-2029)
6.2 North America Compounding Chemotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Compounding Chemotherapy Market Size by Country (2018-2023)
6.4 North America Compounding Chemotherapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Compounding Chemotherapy Market Size (2018-2029)
7.2 Europe Compounding Chemotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Compounding Chemotherapy Market Size by Country (2018-2023)
7.4 Europe Compounding Chemotherapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Compounding Chemotherapy Market Size (2018-2029)
8.2 Asia-Pacific Compounding Chemotherapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Compounding Chemotherapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Compounding Chemotherapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Compounding Chemotherapy Market Size (2018-2029)
9.2 Latin America Compounding Chemotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Compounding Chemotherapy Market Size by Country (2018-2023)
9.4 Latin America Compounding Chemotherapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Compounding Chemotherapy Market Size (2018-2029)
10.2 Middle East & Africa Compounding Chemotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Compounding Chemotherapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Compounding Chemotherapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Braun Melsungen AG
11.1.1 Braun Melsungen AG Company Detail
11.1.2 Braun Melsungen AG Business Overview
11.1.3 Braun Melsungen AG Compounding Chemotherapy Introduction
11.1.4 Braun Melsungen AG Revenue in Compounding Chemotherapy Business (2018-2023)
11.1.5 Braun Melsungen AG Recent Development
11.2 Pfizer Inc.
11.2.1 Pfizer Inc. Company Detail
11.2.2 Pfizer Inc. Business Overview
11.2.3 Pfizer Inc. Compounding Chemotherapy Introduction
11.2.4 Pfizer Inc. Revenue in Compounding Chemotherapy Business (2018-2023)
11.2.5 Pfizer Inc. Recent Development
11.3 Baxter
11.3.1 Baxter Company Detail
11.3.2 Baxter Business Overview
11.3.3 Baxter Compounding Chemotherapy Introduction
11.3.4 Baxter Revenue in Compounding Chemotherapy Business (2018-2023)
11.3.5 Baxter Recent Development
11.4 Grifols SA
11.4.1 Grifols SA Company Detail
11.4.2 Grifols SA Business Overview
11.4.3 Grifols SA Compounding Chemotherapy Introduction
11.4.4 Grifols SA Revenue in Compounding Chemotherapy Business (2018-2023)
11.4.5 Grifols SA Recent Development
11.5 The Metrix Company
11.5.1 The Metrix Company Company Detail
11.5.2 The Metrix Company Business Overview
11.5.3 The Metrix Company Compounding Chemotherapy Introduction
11.5.4 The Metrix Company Revenue in Compounding Chemotherapy Business (2018-2023)
11.5.5 The Metrix Company Recent Development
11.6 Added Pharma
11.6.1 Added Pharma Company Detail
11.6.2 Added Pharma Business Overview
11.6.3 Added Pharma Compounding Chemotherapy Introduction
11.6.4 Added Pharma Revenue in Compounding Chemotherapy Business (2018-2023)
11.6.5 Added Pharma Recent Development
11.7 Equashield
11.7.1 Equashield Company Detail
11.7.2 Equashield Business Overview
11.7.3 Equashield Compounding Chemotherapy Introduction
11.7.4 Equashield Revenue in Compounding Chemotherapy Business (2018-2023)
11.7.5 Equashield Recent Development
11.8 Millers Pharmacy
11.8.1 Millers Pharmacy Company Detail
11.8.2 Millers Pharmacy Business Overview
11.8.3 Millers Pharmacy Compounding Chemotherapy Introduction
11.8.4 Millers Pharmacy Revenue in Compounding Chemotherapy Business (2018-2023)
11.8.5 Millers Pharmacy Recent Development
11.9 Comecer S.P.A.
11.9.1 Comecer S.P.A. Company Detail
11.9.2 Comecer S.P.A. Business Overview
11.9.3 Comecer S.P.A. Compounding Chemotherapy Introduction
11.9.4 Comecer S.P.A. Revenue in Compounding Chemotherapy Business (2018-2023)
11.9.5 Comecer S.P.A. Recent Development
11.10 Omnicell
11.10.1 Omnicell Company Detail
11.10.2 Omnicell Business Overview
11.10.3 Omnicell Compounding Chemotherapy Introduction
11.10.4 Omnicell Revenue in Compounding Chemotherapy Business (2018-2023)
11.10.5 Omnicell Recent Development
11.11 Icon group
11.11.1 Icon group Company Detail
11.11.2 Icon group Business Overview
11.11.3 Icon group Compounding Chemotherapy Introduction
11.11.4 Icon group Revenue in Compounding Chemotherapy Business (2018-2023)
11.11.5 Icon group Recent Development
11.12 Dedalus Group
11.12.1 Dedalus Group Company Detail
11.12.2 Dedalus Group Business Overview
11.12.3 Dedalus Group Compounding Chemotherapy Introduction
11.12.4 Dedalus Group Revenue in Compounding Chemotherapy Business (2018-2023)
11.12.5 Dedalus Group Recent Development
11.13 Arxium
11.13.1 Arxium Company Detail
11.13.2 Arxium Business Overview
11.13.3 Arxium Compounding Chemotherapy Introduction
11.13.4 Arxium Revenue in Compounding Chemotherapy Business (2018-2023)
11.13.5 Arxium Recent Development
11.14 Sterline S.R.L.
11.14.1 Sterline S.R.L. Company Detail
11.14.2 Sterline S.R.L. Business Overview
11.14.3 Sterline S.R.L. Compounding Chemotherapy Introduction
11.14.4 Sterline S.R.L. Revenue in Compounding Chemotherapy Business (2018-2023)
11.14.5 Sterline S.R.L. Recent Development
11.15 Loccioni
11.15.1 Loccioni Company Detail
11.15.2 Loccioni Business Overview
11.15.3 Loccioni Compounding Chemotherapy Introduction
11.15.4 Loccioni Revenue in Compounding Chemotherapy Business (2018-2023)
11.15.5 Loccioni Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details